🇺🇸 FDA
Patent

US 11065332

Combination therapy of immunotoxin and checkpoint inhibitor

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 11065332 (Combination therapy of immunotoxin and checkpoint inhibitor) held by The Government of The United States as Represented by the Secretary of Health and Human Services, National Institutes of Health expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Government of The United States as Represented by the Secretary of Health and Human Services, National Institutes of Health
Grant date
Tue Jul 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K38/164, A61K39/395